← All trials
NCT04499950
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- Nov 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Aug 5, 2020
- Last posted
- Dec 11, 2020
- Enrollment
- 55
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Johns Hopkins UniversityLead sponsor
- Johns Hopkins UniversityCollaborator
- Johns Hopkins UniversityOverall official - principal investigator
- Breast Cancer Research FoundationCollaborator
- American Institute for Cancer Research (AICR)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.